mGluR5 negative allosteric modulator

This page covers all mGluR5 negative allosteric modulator drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting mGluR5 (metabotropic glutamate receptor 5).

Targets

mGluR5 (metabotropic glutamate receptor 5)

Phase 2 pipeline (1)

• AFQ056 with L-dopa · Novartis · Neurology
  AFQ056 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator that reduces excessive glutamatergic signaling, combined with L-dopa to enhance dopaminergic activity in Parkinson's disease.

Patent intelligence

• mglur5 negative allosteric modulator patent landscape — aggregated cliff calendar, attackable patents, originator estates